Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

PubWeight™: 4.77‹?› | Rank: Top 1%

🔗 View Article (PMID 16857570)

Published in Lancet Neurol on August 01, 2006

Authors

Marieke van Oijen1, Albert Hofman, Holly D Soares, Peter J Koudstaal, Monique M B Breteler

Author Affiliations

1: Department of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands.

Articles citing this

(truncated to the top 100)

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55

Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21

Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51

Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension (2012) 1.96

Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology (2008) 1.71

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47

Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44

A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44

Body fluid biomarkers in Alzheimer's disease. Ann Transl Med (2015) 1.44

Aβ(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Biol (2015) 1.42

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40

Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.38

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol (2012) 1.37

Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37

Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25

Plasma Abeta in Alzheimer's disease--up or down? Lancet Neurol (2006) 1.24

Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry (2012) 1.20

Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients. Crit Care (2011) 1.19

Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol (2007) 1.19

Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry (2008) 1.18

New developments in the diagnosis of dementia. Dtsch Arztebl Int (2010) 1.16

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PLoS One (2011) 1.15

A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 1.14

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry (2010) 1.13

Plasma ß-amyloid and cognitive decline. Arch Neurol (2010) 1.13

Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12

Biomarkers in translational research of Alzheimer's disease. Neuropharmacology (2010) 1.11

Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis (2009) 1.10

Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener (2007) 1.06

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther (2013) 1.06

Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol (2008) 1.04

Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem (2008) 1.03

Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med (2009) 1.03

Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm (Vienna) (2006) 1.01

Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol (2009) 1.01

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta (2008) 1.01

Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med (2008) 0.98

Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis (2009) 0.98

Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets (2009) 0.97

Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology (2010) 0.96

Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. J Alzheimers Dis (2014) 0.95

Protein binding in patients with late-life depression. Arch Gen Psychiatry (2011) 0.94

Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. Alzheimers Res Ther (2013) 0.94

High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients. Mol Med (2009) 0.94

Nutrient intake and plasma β-amyloid. Neurology (2012) 0.93

Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment. Neurology (2011) 0.92

Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. Int J Alzheimers Dis (2012) 0.92

Brain and circulating levels of Aβ1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke (2012) 0.91

Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis (2011) 0.91

Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging (2011) 0.90

Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord (2009) 0.90

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.90

Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology (2009) 0.88

Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Mol Med (2009) 0.87

Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep (2016) 0.86

Association of plasma Aß peptides with blood pressure in the elderly. PLoS One (2011) 0.86

Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.86

Alzheimer's Disease in Adults with Down Syndrome. Int Rev Res Ment Retard (2008) 0.86

Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. Int J Alzheimers Dis (2010) 0.85

Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis. Lancet Neurol (2006) 0.85

Neurochemical dementia diagnostics: assays in CSF and blood. Eur Arch Psychiatry Clin Neurosci (2008) 0.84

How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis? Eye (Lond) (2015) 0.84

Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study. J Alzheimers Dis (2013) 0.84

Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease. Neurobiol Aging (2013) 0.84

Adhesion of monocytes to type I collagen stimulates an APP-dependent proinflammatory signaling response and release of Abeta1-40. J Neuroinflammation (2010) 0.82

The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord (2009) 0.82

Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? J Cell Mol Med (2008) 0.82

A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly. Mol Psychiatry (2014) 0.82

Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease. J Neural Transm (Vienna) (2009) 0.82

Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele. PLoS One (2014) 0.81

Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. Front Neurol (2015) 0.81

Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry (2010) 0.81

Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. World J Psychiatry (2011) 0.81

Toward a plasma marker for Alzheimer disease: some progress, but still a long way to go. Neurology (2008) 0.81

Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study. Alzheimer Dis Assoc Disord (2012) 0.81

Biomarkers in Alzheimer's disease: a review. ISRN Pharmacol (2012) 0.80

Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors. J Neural Transm (Vienna) (2011) 0.80

Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis. Lancet Neurol (2006) 0.80

Biomarkers of the dementia. Int J Alzheimers Dis (2011) 0.79

Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn (2015) 0.79

Rescuing apoptotic neurons in Alzheimer's disease using wheat germ agglutinin-conjugated and cardiolipin-conjugated liposomes with encapsulated nerve growth factor and curcumin. Int J Nanomedicine (2015) 0.79

Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis (2011) 0.78

Effect of stent-assisted angioplasty on cognitive status and serum levels of amyloid beta in patients with intracranial and/or extracranial artery stenosis. Neuropsychiatr Dis Treat (2015) 0.78

Circulating biomarkers that predict incident dementia. Alzheimers Res Ther (2014) 0.77

Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2. Hum Genet (2012) 0.77

A positive correlation between serum amyloid β levels and depressive symptoms among community-dwelling elderly individuals in Japan. Neuropsychiatr Dis Treat (2014) 0.77

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77

A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. SAGE Open Med (2015) 0.77

Amyloid β levels in human red blood cells. PLoS One (2012) 0.77

Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol (2015) 0.76

Age-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice. Sci Rep (2016) 0.76

Neurochemical biomarkers in Alzheimer's disease and related disorders. Ther Adv Neurol Disord (2012) 0.76

Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. Front Neurol (2017) 0.75

Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res Ther (2017) 0.75

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma. J Alzheimers Dis (2016) 0.75

Robust risk prediction with biomarkers under two-phase stratified cohort design. Biometrics (2016) 0.75

Centella asiatica extract protects against amyloid β1-40-induced neurotoxicity in neuronal cells by activating the antioxidative defence system. J Tradit Complement Med (2015) 0.75

Articles by these authors

Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35

Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01

A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med (2014) 18.12

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32

Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09

Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85

Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med (2003) 10.61

Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16

Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23

Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89

Incidental findings on brain MRI in the general population. N Engl J Med (2007) 8.59

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation (2006) 8.18

Epidemiology of Parkinson's disease. Lancet Neurol (2006) 8.13

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94

Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J Infect Dis (2008) 7.45

Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89

Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81

The Rotterdam Study: objectives and design update. Eur J Epidemiol (2007) 5.78

Silent brain infarcts: a systematic review. Lancet Neurol (2007) 5.76

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med (1991) 5.69

New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol (2006) 5.39

Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet (2002) 5.32

Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32

Genomewide association studies of stroke. N Engl J Med (2009) 5.29

Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20

Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91

Physical activity, including walking, and cognitive function in older women. JAMA (2004) 4.90

Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78

Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke (2003) 4.78

Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73

GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71

High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care (2007) 4.69

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63

Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet (2009) 4.56

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46

Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation (2004) 4.45

Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38

A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37

Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28

Meta-analysis of genome-wide scans for human adult stature identifies novel Loci and associations with measures of skeletal frame size. PLoS Genet (2009) 4.24

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13

Dietary intake of antioxidants and risk of Alzheimer disease. JAMA (2002) 4.01

Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97

Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94

Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89

Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80

Genome-wide association study of PR interval. Nat Genet (2010) 3.73

Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68

Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67

Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55

Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes (2008) 3.54

Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J (2004) 3.52

The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol (2009) 3.44

Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40

Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol (2004) 3.38

Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37

Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain (2005) 3.34

Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med (2004) 3.32

Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation (2005) 3.28

Corticosteroids and the risk of atrial fibrillation. Arch Intern Med (2006) 3.28

Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Incidence and prognosis of transient neurological attacks. JAMA (2007) 3.21

Measuring cognitive function with age: the influence of selection by health and survival. Epidemiology (2008) 3.19